Articles

« go back

New vaccines for global epidemics: Funding for development and manufacture

The Department of Health is to invest up to £10 million in two competition streams in line with the priorities identified by the UK Vaccine Network.

Vaccines are among the most cost-effective medical countermeasure for confronting epidemics or pandemics. Their effectiveness in preventing disease outbreaks has been far-reaching, and their availability could significantly reduce fatalities. Rapid manufacture, deployment and delivery of these vaccines in resource-poor settings are key to containing the spread of disease.

This competition is aimed at supporting the development of vaccine candidates, vaccine platform technology and vaccine manufacturing technology. These new products must have the potential for use in low- and middle-income countries to target a range of human diseases with epidemic potential, as identified by the UK Vaccine Network.

  • Chikungunya
  • Crimean-Congo Haemorrhagic Fever
  • Dengue Virus
  • Ebola
  • Hantavirus
  • Lassa
  • Marburg
  • Middle East Respiratory Syndrome
  • Nipah
  • Plague
  • Rift Valley Fever and
  • Zika

This SBRI competition aims to stimulate the development and manufacture of new immunising agents and their rapid delivery in response to epidemic or pandemic threats.

The competition will be in 2 streams:

  • In stream 1, up to £6 million is available to enable projects to assess the efficacy potential of the proposed product, generate preliminary performance or validation data.
  • In stream 2, up to £4 million is available to enable projects to generate suitable evidence to begin the process towards regulatory approval.

 

Key dates:

Deadline for registration: noon on 27 April 2016

Deadline for applications: noon on 4 May 2016

 

Further information:

Comments
No comments yet. Be the first.

Subscribe to our updates

Subscribe to our newsletters
Follow us on twitter

Join us on LinkedIn

Keep up to date with the latest agri-food and biosciences news, events, funding opportunities and more.

Got a Question?

 

Email us Email Us
Contact a member of our team